Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

"Controls? Controls?? We Don't Need No Stinkin' Controls!"

Brechbiel MW.

Cancer Biother Radiopharm. 2019 Aug;34(6):343-344. doi: 10.1089/cbr.2019.29007.mwb. Epub 2019 Jun 18. No abstract available.

PMID:
31211593
2.

Two Days at the Hunter College Symposium on Radiometals in New York City.

Brechbiel MW.

Cancer Biother Radiopharm. 2018 Oct;33(8):307. doi: 10.1089/cbr.2018.29004.mwb. Epub 2018 Sep 15. No abstract available.

PMID:
30199276
3.

Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Milenic DE, Kim YS, Baidoo KE, Wong KJ, Barkley R, Delgado J, Brechbiel MW.

Cancer Biother Radiopharm. 2018 Jun;33(5):182-193. doi: 10.1089/cbr.2018.2434.

4.

On Reviewing.

Brechbiel MW.

Cancer Biother Radiopharm. 2018 Jun;33(5):167-168. doi: 10.1089/cbr.2018.29003.mwb. No abstract available.

PMID:
29916746
5.

More Thoughts on Standards and Reproducibility.

Brechbiel MW.

Cancer Biother Radiopharm. 2018 Apr;33(3):85-86. doi: 10.1089/cbr.2018.29002.mwb. No abstract available.

PMID:
29641254
6.

A New Era of Cancer Biotherapy and Radiopharmaceuticals.

Brechbiel MW.

Cancer Biother Radiopharm. 2018 Feb;33(1):1-2. doi: 10.1089/cbr.2018.29001.mwb. No abstract available.

PMID:
29466033
7.

Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW.

Dalton Trans. 2017 Oct 31;46(42):14591-14601. doi: 10.1039/c7dt01819c.

8.

Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.

Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW.

Transl Oncol. 2017 Aug;10(4):535-545. doi: 10.1016/j.tranon.2017.04.004. Epub 2017 May 31.

9.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

10.

Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.

Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.

PLoS One. 2016 Jul 28;11(7):e0159904. doi: 10.1371/journal.pone.0159904. eCollection 2016.

11.

Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.

Guérard F, Lee YS, Baidoo K, Gestin JF, Brechbiel MW.

Chemistry. 2016 Aug 22;22(35):12332-9. doi: 10.1002/chem.201600922. Epub 2016 Jun 15.

12.

(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.

Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG.

J Nucl Med. 2016 Oct;57(10):1569-1575. Epub 2016 May 26.

13.
14.

Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.

Burvenich IJ, Farrugia W, Lee FT, Catimel B, Liu Z, Makris D, Cao D, O'Keefe GJ, Brechbiel MW, King D, Spirkoska V, Allan LC, Ramsland PA, Scott AM.

MAbs. 2016 May-Jun;8(4):775-86. doi: 10.1080/19420862.2016.1156285. Epub 2016 Mar 30.

15.

Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers.

Burvenich IJ, Lee FT, O'Keefe GJ, Makris D, Cao D, Gong S, Rigopoulos A, Allan LC, Brechbiel MW, Liu Z, Ramsland PA, Scott AM.

EJNMMI Res. 2016 Dec;6(1):26. doi: 10.1186/s13550-016-0180-0. Epub 2016 Mar 17.

16.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

17.

Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.

Milenic DE, Baidoo KE, Brechbiel MW.

Pharmaceuticals (Basel). 2015 Jul 29;8(3):435-54. doi: 10.3390/ph8030435.

18.

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.

Milenic DE, Molinolo AA, Solivella MS, Banaga E, Torgue J, Besnainou S, Brechbiel MW, Baidoo KE.

Pharmaceuticals (Basel). 2015 Jul 24;8(3):416-34. doi: 10.3390/ph8030416.

19.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, Matsumura M, Kotsuma M, Watanabe R, Venhaus R, Beckman RA, Greenberg J, Scott AM.

J Clin Oncol. 2015 Aug 20;33(24):2609-16. doi: 10.1200/JCO.2014.60.4256. Epub 2015 Jun 29.

20.

First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.

Baum RP, Kulkarni HR, Müller D, Satz S, Danthi N, Kim YS, Brechbiel MW.

Cancer Biother Radiopharm. 2015 May;30(4):152-9. doi: 10.1089/cbr.2014.1747.

Supplemental Content

Loading ...
Support Center